FR05C0033I2 - R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate - Google Patents
R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfateInfo
- Publication number
- FR05C0033I2 FR05C0033I2 FR05C0033C FR05C0033C FR05C0033I2 FR 05C0033 I2 FR05C0033 I2 FR 05C0033I2 FR 05C0033 C FR05C0033 C FR 05C0033C FR 05C0033 C FR05C0033 C FR 05C0033C FR 05C0033 I2 FR05C0033 I2 FR 05C0033I2
- Authority
- FR
- France
- Prior art keywords
- esylate
- indane
- propargyl
- mesylate
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 title 1
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13951793A | 1993-10-18 | 1993-10-18 | |
PCT/US1994/011567 WO1995011016A1 (en) | 1993-10-18 | 1994-10-12 | R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
FR05C0033I1 FR05C0033I1 (hu) | 2005-09-30 |
FR05C0033I2 true FR05C0033I2 (fr) | 2006-12-29 |
Family
ID=22487049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR05C0033C Active FR05C0033I2 (fr) | 1993-10-18 | 2005-08-09 | R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0812190B1 (hu) |
JP (3) | JPH09505806A (hu) |
AT (1) | ATE284208T1 (hu) |
AU (1) | AU1253495A (hu) |
CA (1) | CA2174449C (hu) |
DE (2) | DE122005000044I2 (hu) |
DK (1) | DK0812190T3 (hu) |
ES (1) | ES2235170T3 (hu) |
FR (1) | FR05C0033I2 (hu) |
HU (1) | HU226138B1 (hu) |
IL (1) | IL111240A (hu) |
LU (1) | LU91191I2 (hu) |
MX (1) | MXPA94008019A (hu) |
NL (1) | NL300205I2 (hu) |
PT (1) | PT812190E (hu) |
WO (1) | WO1995011016A1 (hu) |
ZA (1) | ZA948013B (hu) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
US5844003A (en) * | 1991-04-04 | 1998-12-01 | Innovations Foundation | Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function |
ATE346598T1 (de) * | 1994-01-10 | 2006-12-15 | Teva Pharma | 1-aminoindanderivate und zusammensetzungen hiervon |
US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
AU723047B2 (en) * | 1995-02-10 | 2000-08-17 | University Of Toronto Innovations Foundation, The | Deprenyl compounds for treatment of glaucoma |
BR9607057A (pt) * | 1995-03-02 | 1998-06-09 | Scherer Ltd R P | Composições farmacêuticas compreendendo inibidores monoamina oxidase b |
IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
ATE377585T1 (de) | 1996-12-18 | 2007-11-15 | Teva Pharma | Aminoindanderivate |
GB9715082D0 (en) * | 1997-07-17 | 1997-09-24 | Scherer Ltd R P | Treatment of attention deficit hyperactivity disorder and narcolepsy |
CA2319318A1 (en) * | 1998-01-27 | 1999-07-29 | Thomas N. Thomas | Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl |
US6737547B1 (en) | 1998-12-31 | 2004-05-18 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using N-acyl-1H-aminoindenes |
US6492426B1 (en) | 1999-10-27 | 2002-12-10 | Teva Pharmaceutical Industries, Ltd. | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
DK1567152T3 (da) * | 2002-11-15 | 2013-10-07 | Teva Pharma | Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose |
AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
EP1588704A1 (en) * | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
US7815942B2 (en) | 2005-02-23 | 2010-10-19 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
EP1954667B1 (en) * | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
JP2009518433A (ja) | 2005-12-09 | 2009-05-07 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム | 神経保護用の低用量ラドスチギルの使用 |
WO2007098264A2 (en) * | 2006-02-21 | 2007-08-30 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
MX2008012781A (es) * | 2006-04-03 | 2008-10-14 | Teva Pharma | Uso de rasagilina para el tratamiento de sindrome de piernas inquietas. |
EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
KR101459744B1 (ko) | 2006-12-14 | 2014-11-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정성 고형 라사길린 염기 |
MX2009006252A (es) | 2006-12-14 | 2009-10-13 | Teva Pharma | Sal de tanato de rasagilina. |
AU2008296908B2 (en) * | 2007-09-05 | 2014-01-09 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
EP2231582B1 (en) * | 2007-12-24 | 2011-06-22 | Cipla Limited | Process for the synthesis of propargylated aminoindan derivatives |
EP2271612B1 (en) * | 2008-03-31 | 2016-08-10 | Actavis Group PTC EHF | Rasagiline mesylate particles and process for the preparation thereof |
WO2009141737A2 (en) * | 2008-05-23 | 2009-11-26 | Medichem, S.A. | A new method for obtaining an aminoindan mesylate derivative |
US20110184071A1 (en) * | 2008-06-02 | 2011-07-28 | Vinayak Gore | process for the preparation of amines |
CA2723869C (en) * | 2008-06-02 | 2013-07-16 | Generics [Uk] Limited | A process for the preparation of enantiomerically pure amines |
JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
US20100010098A1 (en) | 2008-07-11 | 2010-01-14 | Walter Elffrink | Polymorphs of rasagiline hydrochloride |
AR074637A1 (es) * | 2008-07-18 | 2011-02-02 | Medichem Sa | Formas de sal de adicion acida de r-(+)-n-propargil-1-aminoindano (es decir , base de rasagilina), un compuesto de formula (1), procesos para prepararlos y aislarlos y usos de los mismos |
DE102008064061A1 (de) | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
DK2451771T3 (da) * | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
CN102048717B (zh) † | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
EP2325159A1 (en) | 2009-11-24 | 2011-05-25 | LEK Pharmaceuticals d.d. | Novel salts of rasagiline |
AU2010341499A1 (en) | 2009-12-22 | 2012-08-09 | Teva Pharmaceutical Industries Ltd. | 3-keto-N-propargyl-1-aminoindan |
WO2011080589A2 (en) * | 2009-12-30 | 2011-07-07 | Actavis Group Ptc Ehf | Solid state forms of rasagiline salts |
US9943489B2 (en) * | 2010-02-03 | 2018-04-17 | Pharmatwob Ltd. | Extended release formulations of rasagiline and uses thereof |
WO2011121607A2 (en) | 2010-03-29 | 2011-10-06 | Cadila Healthcare Limited | Rasagiline and its pharmaceutically acceptable salts |
EP2389927A1 (en) | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of rasagiline |
CN102464589A (zh) * | 2010-11-17 | 2012-05-23 | 凯瑞斯德生化(苏州)有限公司 | 雷沙吉兰、其甲磺酸盐及其中间体的制备方法 |
WO2012096635A1 (en) | 2011-01-13 | 2012-07-19 | Fargem Farmasöti̇k Araştirma Geli̇şti̇rme Merkezi̇ Sanayi̇ Ve Ti̇caret A.Ş. | A new method for the synthesis of rasagiline |
WO2012116752A1 (en) | 2011-03-03 | 2012-09-07 | Synthon Bv | Process of resolution of 1-aminoindan |
WO2012153349A2 (en) | 2011-05-04 | 2012-11-15 | Cadila Healthcare Limited | Rasagiline and its pharmaceutically acceptable salts |
CA2851276A1 (en) * | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | R(+)-n-formyl-propargyl-aminoindan |
DE102012000786A1 (de) | 2012-01-18 | 2013-07-18 | Stada Arzneimittel Ag | Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin |
WO2013139387A1 (en) | 2012-03-21 | 2013-09-26 | Synthon Bv | Stabilized pharmaceutical compositions comprising rasagiline salts |
WO2013175493A1 (en) | 2012-04-09 | 2013-11-28 | Cadila Healthcare Limited | Stable oral pharmaceutical compositions |
ES2524865T1 (es) | 2013-02-06 | 2014-12-15 | Galenicum Health S.L. | Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata |
ES2502140T1 (es) | 2013-02-06 | 2014-10-02 | Galenicum Health S.L. | Comprimidos de liberación inmediata de rasagilina hemitartrato |
IN2013MU01782A (hu) * | 2013-05-20 | 2015-06-26 | Cadila Healthcare Ltd |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
ES2042520T3 (es) * | 1986-06-10 | 1993-12-16 | Chiesi Farma Spa | Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. |
IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
IL112819A (en) * | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
-
1994
- 1994-10-11 IL IL11124094A patent/IL111240A/en not_active IP Right Cessation
- 1994-10-12 DE DE200512000044 patent/DE122005000044I2/de active Active
- 1994-10-12 EP EP95903505A patent/EP0812190B1/en not_active Expired - Lifetime
- 1994-10-12 JP JP7512014A patent/JPH09505806A/ja not_active Withdrawn
- 1994-10-12 WO PCT/US1994/011567 patent/WO1995011016A1/en active IP Right Grant
- 1994-10-12 PT PT95903505T patent/PT812190E/pt unknown
- 1994-10-12 DE DE69434178T patent/DE69434178T2/de not_active Expired - Lifetime
- 1994-10-12 AT AT95903505T patent/ATE284208T1/de active
- 1994-10-12 HU HU9601012A patent/HU226138B1/hu active Protection Beyond IP Right Term
- 1994-10-12 DK DK95903505T patent/DK0812190T3/da active
- 1994-10-12 CA CA002174449A patent/CA2174449C/en not_active Expired - Lifetime
- 1994-10-12 AU AU12534/95A patent/AU1253495A/en not_active Abandoned
- 1994-10-12 ES ES95903505T patent/ES2235170T3/es not_active Expired - Lifetime
- 1994-10-13 ZA ZA948013A patent/ZA948013B/xx unknown
- 1994-10-17 MX MXPA94008019A patent/MXPA94008019A/es active IP Right Grant
-
2002
- 2002-10-17 JP JP2002303097A patent/JP2003160481A/ja not_active Withdrawn
-
2005
- 2005-08-09 FR FR05C0033C patent/FR05C0033I2/fr active Active
- 2005-08-10 LU LU91191C patent/LU91191I2/fr unknown
- 2005-08-15 NL NL300205C patent/NL300205I2/nl unknown
-
2009
- 2009-09-24 JP JP2009219662A patent/JP2010018626A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2174449A1 (en) | 1995-04-27 |
DE122005000044I2 (de) | 2007-09-13 |
ATE284208T1 (de) | 2004-12-15 |
ZA948013B (en) | 1995-05-31 |
EP0812190B1 (en) | 2004-12-08 |
ES2235170T3 (es) | 2005-07-01 |
EP0812190A4 (en) | 1998-03-04 |
LU91191I2 (fr) | 2005-10-10 |
HU226138B1 (en) | 2008-05-28 |
JPH09505806A (ja) | 1997-06-10 |
WO1995011016A1 (en) | 1995-04-27 |
EP0812190A1 (en) | 1997-12-17 |
NL300205I1 (nl) | 2005-10-03 |
AU1253495A (en) | 1995-05-08 |
DE69434178T2 (de) | 2005-12-01 |
NL300205I2 (nl) | 2006-03-01 |
IL111240A (en) | 2001-10-31 |
CA2174449C (en) | 2007-01-16 |
MXPA94008019A (es) | 2004-08-10 |
DE122005000044I1 (de) | 2005-12-22 |
PT812190E (pt) | 2005-04-29 |
FR05C0033I1 (hu) | 2005-09-30 |
HUT77934A (hu) | 1998-11-30 |
JP2010018626A (ja) | 2010-01-28 |
IL111240A0 (en) | 1994-12-29 |
JP2003160481A (ja) | 2003-06-03 |
DE69434178D1 (de) | 2005-01-13 |
DK0812190T3 (da) | 2005-04-11 |
HU9601012D0 (en) | 1996-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR05C0033I2 (fr) | R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate | |
DE69829866D1 (de) | Sklerotische prothese für die behandlung von altersweitsichtigkeit und anderen augenkrankheiten | |
DZ2618A1 (fr) | Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie. | |
FR07C0046I2 (fr) | Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b | |
DE69014030D1 (de) | Mittel für die Verhütung und Behandlung von Diarrhöe. | |
ATE131068T1 (de) | Behandlung von pathologischen zuständen und krankheiten. | |
FR2785521B1 (fr) | Dispositif de suspension pour le traitement de prolapsus et d'incontinences urinaires | |
ATA11989A (de) | Mittel zur vorbeugung gegen und behandlung von parodontopathien | |
DE69840091D1 (de) | Rostschutzpigmentzusammensetzung und rostschutzlacke die diese enthalten | |
DE4397173T1 (de) | Verbesserter Damenstrumpf und Halter hierfür | |
BR9612283A (pt) | Composição para o tratamento de manchas em peças de roupa e métodos de tratamento | |
FR2746658B1 (fr) | Valve de drainage implantable pour le traitement de l'hydrocephalie | |
FR2758465B1 (fr) | Composition pour le traitement de l'amiante | |
DZ1988A1 (fr) | Thérapie de combinaison pour le traitement de l'hiv. | |
DE69520268D1 (de) | Behandlung von Legierungen und danach hergestellte Gegenstände | |
FR2781504B1 (fr) | Foulon pour le traitement des cuirs, peaux et similaires | |
DE59002772D1 (de) | Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms. | |
MA23837A1 (fr) | Benzamides pour le traitement de degenerescenses neurologiques | |
DZ3320A1 (fr) | Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine | |
FR2658419B1 (fr) | Medicament pour le traitement de la dermatite. | |
FR2759290B1 (fr) | Minalcipran pour le traitement de l'incontinence urinaire | |
FR2686246B3 (fr) | Orthese de poignet pour le traitement de l'epicondylalgie. | |
FR2745719B1 (fr) | Composition pour le traitement d'affections cutanees | |
DE69506459D1 (de) | Zwirnverfahren und Zwirnvorrichtung | |
ATE228014T1 (de) | Zusammensetzungen und ihre anwendungen gegen die hyperakute abstossung von transplantaten und bestimmte krankheiten |